SavedAdd your journal

Journals / Psikiyatride Güncel Yaklaşımlar / 2016 / Cilt: 8 - Sayı: 1

Use of Modafinil in Psychiatric Disorders

Psikiyatrik Bozukluklarda Modafinil Kullanımı

Mehmet KOKAÇYA
Ümit ÇÖPOĞLU
Musa ŞAHPOLAT
Mustafa ARI
Pages
42–51
Publication Date
2016-01-23
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this article is to review the literature on clinical use of modafinil in psychiatric disorders.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Modafinil, is a psychostimulant drug with neurochemical and behavourial effects, distinct from those of amphetamine.
📊
Key Findings & Data:It is used to treat patients with narcolepsy and other excessive sleepiness.
💡
Conclusion & Impact:The aim of this article is to review the literature on clinical use of modafinil in psychiatric disorders.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Modafinil · psikiyatrik hastalıklar · ekleme tedavisi

Abstract

Modafinil, is a psychostimulant drug with neurochemical and behavourial effects, distinct from those of amphetamine. It is used to treat patients with narcolepsy and other excessive sleepiness. Modafinil has dopaminergic, noradrenergic, histaminergic, glutamergic, serotonergic and GABAergic interac-tions. It is also shown that modafinil has neuroprotective effects via antioxidative mechanisms. Besides modafinil shows initial promise for a variety of off-label indications in psychiatry, including bipolar disorder, attention-deficit/hyperactivity disorder, and schizophrenia. The aim of this article is to review the literature on clinical use of modafinil in psychiatric disorders.

Özet

Modafinil narkolepsi ve diğer gündüz uykululuğu yapan hastalıklarda kullanılan amfetaminden farklı nörokimyasal ve davranışsal özellikleri olan psikostimulan bir ilaçtır. Modafinilin dopaminerjik, histaminerjik, noradrenerjik glutamaterjik, GABAerjik ve serotoninerjik etkileşimleri vardır. Ayrıca antioksidatif mekanizmalar aracılığıyla nöroprotektif etkilerinin olduğu da gösterilmiştir. Bunun yanında modafinil; bipolar bozukluk, dikkat eksikliği hiperaktivite bozukluğu ve şizofreni gibi psikiyatrik hastalıklarda endikasyon dışı kullanımıyla ilgili gelecek vaadetmektedir. Bu derlemede modafinilin psikiyatrik hastalıklarda klinik kullanımın ele alınması amaçlanmıştır.

🔖

Cite This Article

KOKAÇYA, M., ÇÖPOĞLU, Ü., ŞAHPOLAT, M., ARI, M. (2016). Use of Modafinil in Psychiatric Disorders. Psikiyatride Güncel Yaklaşımlar, Cilt: 8 - Sayı: 1, 42–51. https://ajindex.com/articles/229868

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Aktas O, Yalvac HD (2015) Modafinil-induced psychosis: a case report. Archives of Neuropsychiatry, 52:99-101.
  2. Amiri S, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Kahbazi M, Akhondzadeh S (2008) Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry, 32:145-149.
  3. Andrade C, Kisely S, Monteiro I, Rao S (2015) Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Psychiatr Res, 60:14-21.
  4. Antonelli T, Ferraro L, Hillion J, Tomasini MC, Rambert FA, Fuxe K (1998) Modafinil prevents glutamate cytotoxicity in cultured cortical neurons. Neuroreport, 9:4209–4213.
  5. APA (2010) Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. Arlington, American Psychiatric Association. Ballon JS, Feifel D (2006) A systematic review of modafinil: potential clinical uses and mechanisms of action. J Clin Psychiatry, 67:554 -566. Belmaker RH (2007) Modafinil add-on in the treatment of bipolar depression. Am J Psychiatry, 164:1143-1145.
  6. Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ et al. (2005) Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics, 116:777-784.
  7. Cephalon, Inc. Provigil (modafinil) prescribing information. Cephalon, Inc, West Chester, PA. USA. 2004.
  8. Conners CK, Sitarenios G, Parker JD, Epstein JN (1998) The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol, 26:257-268.
  9. DeBattista C, Doghramji K, Menza MA,Rosenthal MH, Fieve RR (2003) Adjunct modafinil for the shortterm treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry, 64:1057–1064. Dell’Osso B, Dobrea C, Cremaschi L, Arici C, Altamura AC (2014) Wake-promoting pharmacotherapy for psychiatric disorders. Curr Psychiatry Rep, 16:524. Edgar DM, Seidel WF (1997) Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther, 283:757-769.
  10. Elovic E (2000) Use of Provigil for underarousal following TBI. J Head Trauma Reha